1361386-45-9

Basic information

• Product Name: methyl 5-(tert-butyl)-3-methylthiophene-2-carboxylate
• Synonyms: methyl 5-(tert-butyl)-3-methylthiophene-2-carboxylate
• CAS NO: 1361386-45-9
• Molecular Formula: C11H16O2S
• Molecular Weight: 212.313
• Mol File: 1361386-45-9.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 272.8±28.0 °C(Predicted)
• Density: 1.062±0.06 g/cm3(Predicted)
• CAS DataBase Reference: methyl 5-(tert-butyl)-3-methylthiophene-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 5-(tert-butyl)-3-methylthiophene-2-carboxylate(1361386-45-9)
• EPA Substance Registry System: methyl 5-(tert-butyl)-3-methylthiophene-2-carboxylate(1361386-45-9)

Safety Data

• Hazardous Substances Data: 1361386-45-9(Hazardous Substances Data)

Upstream product

• 23806-24-8 3-methyl-2-thiophenecarboxylic acid 
• 81452-54-2 methyl 3-methylthiophene-2-carboxylate 
• 507-20-0 tertiary butyl chloride 
• 61341-26-2 3-methylthenoyl chloride 

Downstream Products

• 1361386-46-0 3-bromomethyl-5-tert-butylthiophene-2-carboxylic acid methyl ester 
• 1361386-47-1 methyl 3-{[(3-bromo-2-methylphenyl)amino]methyl}-5-(tert-butyl)thiophene-2-carboxylate 
• 1361386-48-2 3-{[(3-bromo-2-methylphenyl)amino]methyl}-5-(tert-butyl)thiophene-2-carboxylic acid 
• 1361386-49-3 5-(3-bromo-2-methylphenyl)-2-(tert-butyl)-4H-thieno[2,3-c]pyrrol-6(5H)-one 
• 1361386-50-6 2-(tert-butyl)-5-[2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-4H-thieno[2,3-c]pyrrol-6(5H)-one 
• 1607005-71-9 3-[(4-bromo-2-fluorobenzylamino)methyl]-5-tert-butylthiophene-2-carboxylic acid methyl ester 
• 1610472-59-7 2-tert-butyl-5-{2-fluoro-4-[2-methoxy-6-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl]benzyl}-4,5-dihydrothieno[2,3-c]pyrrol-6-one 
• 1610472-58-6 5-tert-butyl-3-({2-fluoro-4-[2-methoxy-6-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl]benzylamino}methyl)thiophene-2-carboxylic acid 
• 1610472-57-5 5-tert-butyl-3-({2-fluoro-4-[2-methoxy-6-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl]benzylamino}methyl)thiophene-2-carboxylic acid methyl ester 
• 1610472-29-1 2-tert-butyl-5-{2-fluoro-4-[6-(1-methyl-1H-pyrazol-4-yl)-2-oxo-1,2-dihydro-pyridin-4-yl]-benzyl}-4,5-dihydro-thieno[2,3-c]pyrrol-6-one 
• 1361940-93-3 2-tert-butyl-5-(2-methyl-3-(4-methyl-6-(4-(4-methyl-3-oxopiperazin-2-yl)phenylamino)-5-oxo-4,5-dihydropyrazin-2-yl)phenyl)-4H-thieno[2,3-c]pyrrol-6(5H)-one 
• 1361940-92-2 tert-butyl 2-(4-(6-(3-(2-tert-butyl-6-oxo-4H-thieno[2,3-c]pyrrol-5(6H)-yl)-2-methylphenyl)-4-methyl-3-oxo-3,4-dihydropyrazin-2-ylamino)phenyl)-4-methyl-3-oxopiperazine-1-carboxylate 
• 1361941-11-8 2-bromo-6-(2-tert-butyl-6-oxo-4H-thieno[3,2-c]pyrrol-5(6H)-yl)benzyl acetate 
• 1361941-10-7 5-(3-bromo-2-(hydroxymethyl)phenyl)-2-tert-butyl-4H-thieno[3,2-c]pyrrol-6(5H)-one 

Relevant articles and documents

NOVEL TRIAZINE DERIVATIVE

To provide a novel triazine derivative represented by the following formula (I): A triazine derivative represented by the following formula (I) : wherein R1 represents a substituted or unsubstituted aryl group, a substituted or unsubstituted he

INHIBITORS OF BRUTON'S TYROSINE KINASE

This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.

PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF

Pyridone and pyrazinone compounds of Formula (I) including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.